Muscle synergies demonstrate only minimal changes after treatment in cerebral palsy

Table 2 Participant outcomes

Treatment	N	Speed		GDI		N₉₀		tVAF₁
		Pre	Post	Pre	Post	Pre	Post	Pre	Post
BTA	52	0.32 (0.14)	0.30 (.015)	74.4 (12.2)	74.6 (11.2)	2.87 (0.66)	2.73 (0.69)	0.79 (0.06)	0.80 (0.06)
SDR	38	0.34 (0.12)	0.30 (.011)	73.8 (10.2)	76.6 (13.1)	2.74 (0.50)	2.61 (0.75)	0.80 (0.05)	0.82 (0.05)
SEMLS	57	0.29 (0.11)	0.24 (.013)	66.4 (11.7)	76.8 (12.2)	2.72 (0.70)	2.61 (0.73)	0.80 (0.06)	0.80 (0.06)
TD	31	0.50 (0.09)	–	93.6 (9.3)	–	4.19 (0.40)	–	0.64 (0.03)	–

NOTE. Values are average (1 SD) or as otherwise indicated
N Number of Participants, Post Post-Treatment, Pre Pre-Treatment,
Speed Non-Dimensional Walking Speed, GDI Gait Deviation Index, N₉₀ Number of Synergies,
tVAF₁ Total Variance Accounted for By One Synergy, BTA Botulinum Toxin Type A Injection,
SDR Selective Dorsal Rhizotomy, SEMLS Single Event Multi-Level Orthopaedic Surgery,
TD Typically-Developing Children

ISSN: 1743-0003